Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
NOTV | US
0.08
91.80%
Healthcare
Diagnostics & Research
30/06/2024
05/06/2026
0.17
0.09
0.30
0.08
Inotiv Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies universities government research centers and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models diets bedding and bioproducts. The company offers research and discovery services including computational toxicology disease pharmacology DMPK safety pharmacology discovery bioanalysis exploratory surgical models and medical device and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology regulated bioanalysis biotherapeutics and development and reproductive toxicology; pathology services such as histology digital clinical and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis biotherapeutics and regulated preclinical and clinical bioanalysis; proteomics; and consulting services. The company operates in the United States rest of North America the Pacific Rim Europe and internationally. The company was formerly known as Bioanalytical Systems Inc. and changed its name to Inotiv Inc. in March 2021. Inotiv Inc. was incorporated in 1974 and is headquartered in West Lafayette Indiana.
View LessStrength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Value Stock (Price to Book < 3)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
589.6%1 month
404.7%3 months
280.8%6 months
213.4%-
-
0.24
2.36
0.55
24.77
0.92
-
19.05M
4.32M
4.32M
-
-17.29
-
-32.80
-43.15
8.44
5.50
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.24
Range1M
0.26
Range3M
0.41
Rel. volume
20.92
Price X volume
176.98M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| iSpecimen Inc. Common Stock | ISPC | Diagnostics & Research | 3.02 | 1.98M | -5.03% | n/a | 0.48% |
| Streamline Health Solutions Inc | STRM | Health Information Services | 0.405 | 1.71M | n/a | 78.40% | |
| Mangoceuticals Inc. Common Stock | MGRX | Health Information Services | 0.357 | 856.80K | -8.30% | n/a | 1.92% |
| Common Stock | ZCMD | Health Information Services | 0.026 | 145.99K | -28.18% | n/a | 4.49% |
| TALKW | TALKW | Health Information Services | 0.0026 | 0 | -13.33% | n/a | 0.00% |
| LifeMD Inc. 8.875% Series A Cumulative Perpetual Preferred Stock | LFMDP | Health Information Services | 23.6 | 0 | -0.21% | n/a | -494.85% |
| EUDA Health Holdings Limited | EUDAW | Health Information Services | 0.0227 | 0 | -13.36% | n/a | -42.31% |
| Bullfrog AI Holdings Inc. Warrants | BFRGW | Health Information Services | 0.1401 | 0 | -7.22% | n/a | 6.33% |
| Heartbeam Inc. Warrant | BEATW | Health Information Services | 0.06 | 0 | n/a | 0.00% | |
| STRRP | STRRP | Diagnostics & Research | 9.73 | 0 | 0.31% | n/a | 26.85% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.32 | 3.37M | -13.16% | n/a | 17.32% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 0.3876 | 213.57K | -7.71% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 24.77 | 12.67 | Expensive |
| Ent. to Revenue | 0.92 | 44.00 | Cheaper |
| PE Ratio | - | 40.09 | - |
| Price to Book | 0.24 | 77.50 | Cheaper |
| Dividend Yield | - | 1.18 | - |
| Std. Deviation (3M) | 280.84 | 59.59 | Riskier |
| Debt to Equity | 2.36 | -14.36 | Expensive |
| Debt to Assets | 0.55 | 0.34 | Expensive |
| Market Cap | 4.32M | 13.71B | Emerging |